Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01856439
Recruitment Status : Terminated (As a result of termination of development of Prosavin, it is no longer possible for Sio to either commence or to continue any related clinical trials.)
First Posted : May 17, 2013
Last Update Posted : May 3, 2022
Oxford BioMedica
Information provided by (Responsible Party):
Sio Gene Therapies ( Axovant Sciences Ltd. )

Brief Summary:
The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study .

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: ProSavin Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.
Study Start Date : May 2011
Actual Primary Completion Date : November 2021
Actual Study Completion Date : April 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Long term follow up
Long term follow up of patient's who received ProSavin in previous study
Drug: ProSavin
Long term follow up of patients who received ProSavin in a previous study

Primary Outcome Measures :
  1. To assess the long term safety and tolerability of ProSavin [ Time Frame: 10 years ]
    The number and severity of any adverse event

Secondary Outcome Measures :
  1. Patients' responses to ProSavin administration [ Time Frame: 10 years ]
    Assessed using Unified Parkinson's Disease Rating Score(UPDRS) Part III, evaluating percentage of time during waking day that patient is in the "off" state through patient diaries and activities of daily living using PDQ-39 at 36 months post administration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • must have met all inclusion criteria for study PS1/001/07
  • willing to have L-DOPA dosage reduced/withdrawn at the discretion of the investigator at regular intervals to allow assessment of ProSavin in the absence of concomitant antiparkinsonian medication.
  • affiliated with the French social security health care system (Patients enrolled in France only)
  • signed and dated written informed consent obtained from the patient and/or the patient's legally acceptable representative, if applicable, in accordance with the local regulations
  • must have been treated with ProSavin/Sham

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01856439

Layout table for location information
Henri Mondor Hospital
Paris, France
United Kingdom
Addenbrookes Hospital
Cambridge, United Kingdom
Sponsors and Collaborators
Axovant Sciences Ltd.
Oxford BioMedica
Layout table for investigator information
Principal Investigator: Stephane Palfi, Professor Henri Mondor University Hospital
Principal Investigator: Roger Barker, Dr Addenbrookes Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Axovant Sciences Ltd. Identifier: NCT01856439    
Other Study ID Numbers: PS1/001/09
2009-017253-35 ( EudraCT Number )
First Posted: May 17, 2013    Key Record Dates
Last Update Posted: May 3, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Sio Gene Therapies ( Axovant Sciences Ltd. ):
Gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases